The syndrome of inappropriate antidiuretic hormone: Current and future management options

European Journal of Endocrinology

Volumn 162, Issue SUPPL. 1, 2010, Pages

  Sherlock, Mark ^a   Thompson, Chris J ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CONIVAPTAN; DEMECLOCYCLINE; FUROSEMIDE; LITHIUM; LIXIVAPTAN; MOZAVAPTAN; SATAVAPTAN; TOLVAPTAN; UREA; VASOPRESSIN ANTAGONIST; VASOPRESSIN V2 RECEPTOR; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPERPARATHYROIDISM; HYPONATREMIA; HYPOTHYROIDISM; INAPPROPRIATE VASOPRESSIN SECRETION; MORBIDITY; MORTALITY; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; POLYURIA; PRIORITY JOURNAL; RASH; TREMOR; CLINICAL TRIAL; DISEASE MANAGEMENT; DRUG ANTAGONISM; FORECASTING; PHYSIOLOGY; REVIEW; SCHWARTZ BARTTER SYNDROME; TREATMENT OUTCOME;

BENZAZEPINES; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; FORECASTING; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; RECEPTORS, VASOPRESSIN; TREATMENT OUTCOME;

EID: 77953640001     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-1057     Document Type: Article

References (45)

1. Verbalis J. Hyponatraemia Water and Salt Homeostasis in Health and Disease. edn 1, pp. 499-530, London: Baillière Tindall, 1989.
2. Gill G, Huda B, Boyd A, Skagen K, Wile D, Watson I & van Heyningen C. Characteristics and mortality of severe hyponatraemia - a hospital-based study. Clinical Endocrinology 2006 65 246-249. (Pubitemid 44079690)
3. Sajadieh A, Binici Z, Mouridsen MR, Nielsen OW, Hansen JF & Haugaard SB. Mild hyponatremia carries a poor prognosis in community subjects. American Journal of Medicine 2009 122 679-686.
4. Stelfox HT, Ahmed SB, Khandwala F, Zygun D, Shahpori R & Laupland K. The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical-surgical intensive care units. Critical Care 2008 12 R162.
5. Waikar SS, Mount DB & Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. American Journal of Medicine 2009 122 857-865.
6. Sherlock M, O'Sullivan E, Agha A, Behan LA, Rawluk D, Brennan P, Tormey W & Thompson CJ. The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage. Clinical Endocrinology 2006 64 250-254.
7. Arieff AI, Llach F & Massry SG. Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes. Medicine 1976 55 121-129.
8. Renneboog B, Musch W, Vandemergel X, Manto MU & Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits.American Journal of Medicine200611971-78.
9. Gankam KF, Andres C, Sattar L, Melot C & Decaux G. Mild hyponatremia and risk of fracture in the ambulatory elderly. Quarterly Journal of Medicine 2008 101 583-588. (Pubitemid 351912001)
10. Smith DM, McKenna K & Thompson CJ. Hyponatraemia. Clinical Endocrinology 2000 52 667-678.
11. Clayton JA, Le Jeune IR & Hall IP. Severe hyponatraemia in medical in-patients: aetiology, assessment and outcome. Quarterly Journal of Medicine 2006 99 505-511.
12. Hoorn EJ, Lindemans J & Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrology, Dialysis, Transplantation 2006 21 70-76.
13. Chow KM, Kwan BC & Szeto CC. Clinical studies of thiazide-induced hyponatremia. Journal of the National Medical Association 2004 96 1305-1308.
14. Verbalis JG, Barsony J, Sugimura Y, Tian Y, Adams DJ, Carter EA & Resnick HE. Hyponatremia-induced osteoporosis. Journal of Bone and Mineral Research 2009. In press. DOI:10.1359/jbmr.090827.
15. Smith D, Moore K, Tormey W, Baylis PH & Thompson CJ. Downward resetting of the osmotic threshold for thirst in patients with SIADH. American Journal of Physiology. Endocrinology and Metabolism 2004 287 E1019-E1023.
16. Carrilho F, Bosch J, Arroyo V, Mas A, Viver J & Rodes J. Renal failure associated with demeclocycline in cirrhosis. Annals of Internal Medicine 1977 87 195-197. (Pubitemid 8165586)
17. Baylis PH & Heath DA. Water disturbances in patients treated with oral lithium carbonate. Annals of Internal Medicine 1978 88 607-609.
18. Nielsen J, Hoffert JD, Knepper MA, Agre P, Nielsen S & Fenton RA. Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation. PNAS 2008 105 3634-3639. (Pubitemid 351723604)
19. Waller DG, Edwards JG & Papasthatis-Papayanni S. A longitudinal assessment of renal function during treatment with lithium. Quarterly Journal of Medicine 1988 68 553-558.
20. Lindop GB & Padfield PL. The renal pathology in a case of lithium-induced diabetes insipidus. Journal of Clinical Pathology 1975 28 472-475.
21. Thompson CJ, Freeman J, Record CO & Baylis PH. Hypernatraemia due to a reset osmostat for vasopressin release and thirst, complicated by nephrogenic diabetes insipidus. Postgraduate Medical Journal 1987 63 979-982. (Pubitemid 18003139)
22. Walker RG, Escott M, Birchall I, Dowling JP & Kincaid-Smith P. Chronic progressive renal lesions induced by lithium. Kidney International 1986 29 875-881. (Pubitemid 16094016)
23. Grunfeld JP & Rossier BC. Lithium nephrotoxicity revisited. Nature Reviews. Nephrology 2009 5 270-276.
24. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. American Journal of Medicine 2001 110 582-584.
25. Soupart A, Schroeder B & Decaux G. Treatment of hyponatraemia by urea decreases risks of brain complications in rats. Brain osmolyte contents analysis. Nephrology, Dialysis, Transplantation 2007 22 1856-1863.
26. Van Reeth O & Decaux G. Rapid correction of hyponatraemia with urea may protect against brain damage in rats. Clinical Science 1989 77 351-355. (Pubitemid 19221028)
27. Hantman D, Rossier B, Zohlman R & Schrier R. Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. An alternative treatment to hypertonic saline. Annals of Internal Medicine 1973 78 870-875.
28. Musch W & Decaux G. Treating the syndrome of inappropriate ADH secretion with isotonic saline. Quarterly Journal of Medicine 1998 91 749-753. (Pubitemid 28508621)
29. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW & Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. American Journal of Medicine 2007 120 S1-S21.
30. Adrogue HJ & Madias NE. Hyponatremia. New England Journal of Medicine 2000 342 1581-1589.
31. Mohmand HK, Issa D, Ahmad Z, Cappuccio JD, Kouides RW & Sterns RH. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clinical Journal of the American Society of Nephrology 2007 2 1110-1117.
32. Robertson GL, Aycinena P & Zerbe RL. Neurogenic disorders of osmoregulation. American Journal of Medicine 1982 72 339-353.
33. Lien YH & Shapiro JI. Hyponatremia: clinical diagnosis and management. American Journal of Medicine 2007 120 653-658.
34. Shoaf SE, Bramer SL, Bricmont P & Zimmer CA. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a nonpeptide AVP antagonist, and furosemide or hydrochlorothiazide. Journal of Cardiovascular Pharmacology 2007 50 213-222. (Pubitemid 47267748)
35. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS & Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. New England Journal of Medicine 2006 355 2099-2112. (Pubitemid 44749318)
36. Verbalis JG, Zeltser D, Smith N, Barve A & Andoh M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clinical Endocrinology 2008 69 159-168. (Pubitemid 351847263)
37. Annane D, Decaux G & Smith N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. American Journal of the Medical Sciences 2009 337 28-36.
38. Zilberberg MD, Exuzides A, Spalding J, Foreman A, Jones AG, Colby C & Shorr AF. Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study. BMC Pulmonary Medicine 2008 8 16.
39. Shea AM, Hammill BG, Curtis LH, Szczech LA & Schulman KA. Medical costs of abnormal serum sodium levels. Journal of the American Society of Nephrology 2008 19 764-770.
40. Madias NE. Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia. American Journal of Kidney Diseases 2007 50 184-187. (Pubitemid 47095092)
41. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA & Smith N. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. Journal of Clinical Endocrinology and Metabolism 2006 91 2145-2152.
42. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG & Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. American Journal of Nephrology 2007 27 447-457. (Pubitemid 47482001)
43. Wong F, Blei AT, Blendis LM & Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003 37 182-191. (Pubitemid 36042159)
44. Saito T, Ishikawa S, Abe K, Kamoi K, Yamada K, Shimizu K, Saruta T & Yoshida S. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Journal of Clinical Endocrinology and Metabolism 1997 82 1054-1057. (Pubitemid 27166641)
45. Soupart A, Gross P, Legros JJ, Alfoldi S, Annane D, Heshmati HM & Decaux G. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clinical Journal of the American Society of Nephrology 2006 1 1154-1160.